FDA Clears Protamine Sulfate for Generic Versions
Published Date: 6/8/2026
Notice
Summary
The FDA has decided that Protamine Sulfate and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can keep counting on these medicines without any interruptions or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics Can Keep Getting Approved
If you make generic drugs, the FDA determined on June 8, 2026 that the listed products (including Protamine Sulfate 50 mg/5 mL) were not withdrawn for safety or effectiveness. That means FDA will not start proceedings to withdraw ANDA approvals that refer to these drugs and may continue to approve additional ANDAs that refer to them as long as applicants meet legal and regulatory requirements.
Patients and Pharmacies Keep Access
You (patients and pharmacies) can continue to rely on the listed medicines because FDA determined they were not withdrawn for safety or effectiveness and will keep related ANDAs listed and in place. The notice says approved ANDAs referring to these drugs are unaffected and additional ANDAs may be approved if they meet requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11308 — Medical Devices; Orthopedic Devices; Classification of the Resorbable Calcium Salt Bone Void Filler Containing a Single Approved Aminoglycoside Antibacterial
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
2026-11303 — Intent To Exempt Certain Unclassified Medical Devices From Premarket Notification Requirements; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA is planning to exempt some unclassified medical devices from the usual premarket notification rules, making it easier and faster for these devices to reach the market. This change affects manufacturers of certain medical devices and could save them time and money. The new guidance is effective starting June 5, 2026, but the FDA is still open to feedback from the public.
2026-11302 — Medical Devices; Orthopedic Devices; Classification of the Absorbable Metallic Bone Fixation Fastener
The FDA is officially classifying absorbable metallic bone fixation fasteners as Class II devices with special safety rules, making them easier to get to patients while keeping them safe and effective. This change helps doctors and patients by reducing red tape and encouraging new, helpful bone-fixing tech. The new rules took effect on June 5, 2026, but have been in place since March 29, 2023, so manufacturers should already be on board.
2026-11306 — Medical Devices; Orthopedic Devices; Classification of the Shoulder Joint Humeral (Hemi-Shoulder) Ceramic Head/Metallic Stem Cemented or Uncemented Prosthesis
The FDA is officially putting the shoulder joint humeral ceramic head/metallic stem prosthesis into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps patients get safer, innovative shoulder implants faster and makes life easier for makers by lowering regulatory costs. The new classification is effective June 5, 2026, but has been in effect since December 16, 2022.
2026-11054 — Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help companies making gene therapy products that use genome editing. It shows how to use what’s already known to speed up development and get safer, smarter treatments to patients faster. If you’re in this field, send your feedback by September 1, 2026, so your voice shapes the final rules—saving time and money down the road!
2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
Previous / Next Documents
Previous: 2026-11428 — Proposed Information Collection Activity; ACF-700 Tribal Annual Report
Tribal child care programs that get federal money will fill out a shorter, easier annual report called the ACF-700. This update cuts down on repetitive questions and removes old COVID-related data, saving tribes time and effort. Comments on these changes are open until August 7, 2026, so tribes can share their thoughts before it’s finalized.
Next: 2026-11430 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection; Juvenile Facility Census Program (JFCP)
The Department of Justice wants to update how it collects info for the 2027 Juvenile Facility Census Program, which tracks kids under 21 in juvenile facilities. They’re asking for public feedback by August 7, 2026, to make sure the process is clear, useful, and not too much work. This update aims to improve data collection while keeping it easy and efficient for facilities to respond.